Cargando…
Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis
BACKGROUND: Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy. We report our experience using intermediate-dose cyta...
Autores principales: | Liu, Ting, Cai, Hua-cong, Cai, Hao, Chen, Miao, Zhang, Wei, Li, Jian, Zhou, Dao-bin, Cao, Xin-xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822720/ https://www.ncbi.nlm.nih.gov/pubmed/35130950 http://dx.doi.org/10.1186/s13023-022-02193-0 |
Ejemplares similares
-
PB2197: ADULT LANGERHANS CELL HISTIOCYTOSIS WITH LIVER INVOLVEMENT
por: Chang, Long, et al.
Publicado: (2023) -
Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study
por: Cai, Hua-cong, et al.
Publicado: (2022) -
P1039: LOW DOSE CYTARABINE FOR ADULT PATIENTS WITH NEWLY DIAGNOSED LANGERHANS CELL HISTIOCYTOSIS: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY
por: Chang, Long, et al.
Publicado: (2023) -
Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis
por: Lang, Min, et al.
Publicado: (2023) -
Clinical presentation and prognostic analysis of adult patients with Langerhans cell histiocytosis with pulmonary involvement
por: Miao, Hui-lei, et al.
Publicado: (2020)